Abstract:
Etiopathogenesis of benign prostatic hypertroplasia (BPH) remains unclear. There are some difficulties in the BPH studies, including lack of good animal models of BPH disease and the anatomic discrepancy between rodent and human prostates. Aging and the presence of the functional testes are the two established risk factors for the development of BPH. It is generally accepted that androgens are the most critical hormone for the prostate growth but also have been implicated in prostate disease as well. We propose to dissect the BPH biology into stromal cell growth and androgen stimulation of epithelial growth and reflect in growth assays of human prostatic stromal WPMY-1 cells, PSA-report gene assay in human prostate cancer 103 E cells, and the prostate cancer LNCaP orthotopic tumor as cellular and animal models for BPH. Therefore, the platform assays can afford bioactivity-guided isolation to analyze candidate drug for BPH therapeutics.
Fields of Application:
Drug Screening
Advantages when compared to the existing technologies:
The platform assays can afford bioactivity-guided isolation to analyze candidate drug for BPH therapeutics.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
IP Status:Know-how
